We should always be maintaining and reviewing our watchlists. Some times, like now, that is even more important. In-action is the worst reaction.

On Pfizer I own PFE bought at around these prices.
To embellish comments already in this thread, PFE have the best sales machine in the industry. They will either develop or buy products to sell. That is the most probably outcome. Yet look at PFE’s stats and you can see the odds the voting machine is quoting. There is a clear discrepancy there, some call it a margin of safety. There is no binary event risk here as is often the case in bio/pharma. There are lots of products yet to be discovered, developed and sold.

One example:
Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer’s and Huntington’s Diseases read more->

Pfizer are paying up to $750M for that AD drug with $225M up front.

In other news Prana publishes AD results in Lancet They have the current third placed AD compound and are valued at a big but perhaps appropriate discount. A deal is overdue. Binary event, with little downside. With Medivation taken out, Prana is the best looking entry into the AD race for all those pharma companies who need to get some action in their pipeline. (I am indirectly connected to Prana, I hold shares in Prana, my wife holds options)

Related posts:

1. Pfizer Dividend Cut?
2. Prana Biotechnology Secures Additional Funds
3. Unsmegingbelievable – Is BAM Captial Trying to Rort Prana Holders
4. Southern Cross Equities and Prana Biotech
5. Has the Fizz gone from Pfizer?
6. Life Force Draining Out of Prana